Home Stock

Stock Research: Lotus Pharmaceutical

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Lotus Pharmaceutical

TAI:1795 TW0001795003
90
  • Value
    59
  • Growth
    99
  • Safety
    Safety
    28
  • Combined
    69
  • Sentiment
    100
  • 360° View
    360° View
    90
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Lotus Pharmaceutical Co Ltd is a Taiwan-based company focused on manufacturing and selling generic drugs, including solid preparations like tablets and capsules. The company operates in oral anti-cancer drugs, cardiovascular disease drugs, central nervous system drugs, women's health products, osteoporosis drugs, and mental disease drugs, and is also involved in drug research, development, clinical testing, and product licensing. Its main markets are Taiwan, South Korea, the United States, China mainland, Japan, Europe, and Southeast Asia. In the last fiscal year, the company had a market cap of $1963 million, profits of $333 million, and revenue of $567 million.

more
Strongest Rank Leverage
Weakest Rank Sentiment
Country Taiwan
Industry Pharmaceuticals
Size Small
Website lotuspharm.com.tw
Index
FTSE Taiwan
Lotus Pharmaceutical stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
59 38 38 65
Growth
99 80 87 85
Safety
Safety
28 13 18 18
Sentiment
100 100 90 69
360° View
360° View
90 69 70 79
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
93 93 91 95
Opinions Change
90 50 50 50
Pro Holdings
n/a 100 96 4
Market Pulse
89 100 46 79
Sentiment
100 100 90 69
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
59 38 38 65
Growth
99 80 87 85
Safety Safety
28 13 18 18
Combined
69 38 42 57
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
41 24 24 69
Price vs. Earnings (P/E)
77 74 65 91
Price vs. Book (P/B)
33 22 18 47
Dividend Yield
64 67 64 62
Value
59 38 38 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
97 84 82 67
Profit Growth
51 44 69 76
Capital Growth
91 55 51 25
Stock Returns
83 64 71 89
Growth
99 80 87 85
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
19 11 11 8
Refinancing
39 26 29 43
Liquidity
66 22 39 24
Safety Safety
28 13 18 18

Similar Stocks

Discover high‑ranked alternatives to Lotus Pharmaceutical and broaden your portfolio horizons.

CTBC Financial Holding

TAI:2891
Country: Taiwan
Industry: Diversified Banks
Size: Medium
Full Stock Analysis

Galaxy Entertainment

HKG:27
Country: Hong Kong
Industry: Casinos & Gaming
Size: X-Large
Full Stock Analysis

Subaru

TYO:7270
Country: Japan
Industry: Automobile Manufacturers
Size: X-Large
Full Stock Analysis

Wistron

TAI:3231
Country: Taiwan
Industry: Technology Hardware & Peripherals
Size: Large
Full Stock Analysis

Frequently Asked
Questions

This is a classic, high-risk growth play: high growth and positive sentiment outweigh low Value Rank (expensive) and risky financing. This is for aggressive growth investors who are comfortable with the high price and risk, believing the growth story justifies the expense.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews